Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Cream on Itch in Atopic Dermatitis
NCT04839380Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib cream in atopic dermatitis (AD), sponsored by Incyte. Primary endpoint: Peak-Pruritus Numerical Rating Scale at Day 2. Started Oct 2021; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04839380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839380.